OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes
— Trial will evaluate the insulin-sensitizing effects of TLC-3595, alone and in combination with approved diabetes therapies — PALO ALTO, Calif.–(BUSINESS WIRE)–OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase […]
OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders
— Company to share clinical and preclinical data on ACC2, LXR, mitochondrial protonophore, and ACMSD programs — OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the company’s programs at AASLD’s The Liver Meeting® from November 4-8. OrsoBio recently announced that it has acquired novel […]
OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals
— Company will present preclinical data at The Liver Meeting® as it continues Phase 1 clinical trial for TLC-2716 — Palo Alto, Calif. – November 2, 2022 – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse […]
